Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$0.09
EPS est.
$0.01
EPS surprise
+800.00%
1-day move
+12.87%
Cronos Group's strong earnings report, highlighted by a significant EPS beat and record revenue, led to a 12.87% increase in stock price. The growth was driven by higher sales volumes and average selling prices, particularly in international markets. This positive momentum may enhance investor confidence as the company continues to expand its market presence.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.09 | N/A | +800.00% |
| Revenue | $53 million | N/A | N/A |
| Gross Profit | $28.5 million | N/A | N/A |
| Adjusted EBITDA | $13.1 million | N/A | N/A |
Management expressed confidence in the company's performance, highlighting record revenue and gross profit. They noted strong contributions from international markets, particularly Israel and Germany.
We achieved record net revenue and gross profit this quarter.
Our international markets are showing significant growth.
Cronos Group Inc. is a health care company focused on the production and sale of cannabis products. As a player in the pharmaceuticals industry, it operates in a rapidly evolving market that is increasingly recognized for its potential therapeutic benefits.
Last quarter
In Q1-2026, Cronos reported an EPS of $0.04, significantly surpassing expectations. The stock reacted positively, gaining over 8% the following day.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
50%
Avg EPS surprise
+279.17%
Avg 1-day reaction
+8.19%
Investors are cautiously optimistic ahead of the earnings report, especially given the company's recent performance. However, the lack of analyst estimates adds uncertainty to expectations.
Bull case
If Cronos can show strong revenue growth and maintain or improve its EPS, it could significantly boost investor confidence and stock price.
Bear case
Conversely, if the company fails to meet expectations for revenue or EPS, it could lead to a sharp decline in stock price, especially given the high implied volatility.
The print will turn on these.
Q1
What is the revenue growth rate compared to last quarter?
This will help gauge the company's ability to expand in a competitive market and will be critical for investor confidence.
Q2
How does the company plan to address any potential challenges in the cannabis market?
Understanding management's strategy for navigating market challenges will be crucial for assessing future performance.
—
Est. EPS
$1.00
Est. Rev
$14.1B
Impl. Move
±11.9%
Why consensus could be wrong
The Street may underestimate Cronos' ability to capitalize on emerging cannabis markets, particularly if they can demonstrate strong revenue growth despite industry challenges.
Supporting evidence
Recent earnings surprises indicate a potential for continued positive performance.
Options pricing suggests a significant move, which may reflect greater investor confidence than analysts predict.
Key risk
If revenue growth exceeds expectations, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is keenly focused on growth metrics, especially in a sector that is still maturing.
Bull confirmed if
Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bull case.
Bear confirmed if
If revenue growth is flat or negative, it would support the bear case.
What the market is pricing for the move.
Implied Move
±33.86%
Historical Avg
±8.2%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.
Options are pricing ±33.9% while CRON has averaged ±8.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
43.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
15.49%
of float
Insider
49.14%
of float
Holders
239
institutions
Top Holders· as of Jun 2026
Shaw D.E. & Co., Inc.
8,840,503 sh · $28.6M
2.40%
16.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cronos beats expectations, history suggests a potential stock increase of around 10.37%, confirming bullish sentiment.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
Should the company miss expectations, history indicates a potential decline of about 7.48%, leading to increased caution among investors.
The lines on the call that would change the story.
Chescapmanager LLC
7,942,737 sh · $25.7M
2.16%
Flat
Tidal Investments LLC
3,767,849 sh · $12.2M
1.02%
-6.4%
Dimensional Fund Advisors LP
3,048,254 sh · $9.9M
0.83%
13.8%
Arrowstreet Capital, Limited Partnership
1,992,855 sh · $6.5M
0.54%
100.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.